Robert R. Bonczek, Mba, Jd
President and Chief Financial Officer, MedBlue Inc
Chemical Computing Group
Mr. Bonczek has been instrumental in helping companies through IPOs, secondary equity offerings, private placements, transactional advice for M&As, strategic planning, and collaboration agreements. He has served as President, Director, CFO and General Counsel of b3 bio, Inc.; CFO, General Counsel and Chief Administrative Officer of Trimeris, Inc.; Chief Counsel and Global Director of Safety, Health and Environment, Dupont; CFO, Enci Therapeutics, Inc.; and CFO, C2 Regenerate, Inc.
Mr. Bonczek is founding partner, Director and President of Aspen Tree Capital. He also serves on the boards of several other life science-related companies including NeurOp, Inc., Senex Biotechnology, Upstream Therapeutics, Inc., Deep Blue Medical Advances, Inc., Track X Technology, Cellective Biotherapy, Inc., and Istari Oncology, Inc. He also serves on advisory boards for several companies, including Valence Advantage Life Sciences Fund, and Centre Partners. Mr. Bonczek received an AB in chemistry and a JD degree from the University of North Carolina. He also holds an MBA from the Wharton School at the University of Pennsylvania.